

**GOT1B Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13094b****Specification**

---

**GOT1B Antibody (C-term) Blocking peptide - Product Information**Primary Accession [Q9Y3E0](#)**GOT1B Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 51026**Other Names**

Vesicle transport protein GOT1B, Germ cell tumor 2, Golgi transport 1 homolog B, Putative NF-kappa-B-activating protein 470, hGOT1a, GOLT1B, GCT2, GOT1A

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13094b was selected from the C-term region of GOT1B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**GOT1B Antibody (C-term) Blocking peptide - Protein Information****Name** GOLT1B**Synonyms** GCT2, GOT1A**Function**

May be involved in fusion of ER-derived transport vesicles with the Golgi complex.

**Cellular Location**

Golgi apparatus membrane; Multi-pass membrane protein

**Tissue Location**

Widely expressed. Tends to be up-regulated in seminomas compared to normal testis.

**GOT1B Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**GOT1B Antibody (C-term) Blocking peptide - Images****GOT1B Antibody (C-term) Blocking peptide - Background**

GOT1B may be involved in fusion of ER-derived transport vesicles with the Golgi complex.

**GOT1B Antibody (C-term) Blocking peptide - References**

Lamesch, P., et al. Genomics 89(3):307-315(2007)Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)Matsuda, A., et al. Oncogene 22(21):3307-3318(2003)Bourdon, V., et al. Cancer Res. 62(21):6218-6223(2002)Simpson, J.C., et al. EMBO Rep. 1(3):287-292(2000)